Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment
Translational Research · 2024
DOI: 10.1016/j.trsl.2023.10.005 ↗Kurz gefasst
Fachartikel in der Zeitschrift Translational Research, 2024. Verfasst von Pattareeya Yottasan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, University of California, San Francisco, 513 Parnassus Avenue, HSE 1244, San Francisco, CA, 94143, United States. Hauptthemen laut MEDLINE: Polycystic Kidney, Autosomal Dominant, Cysts. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, National Institutes of Health, University of Kansas.
Abstract (Originalsprache)
ADPKD is characterized by progressive cyst formation and enlargement leading to kidney failure. Tolvaptan is currently the only FDA-approved treatment for ADPKD; however, it can cause serious adverse effects including hepatotoxicity. There remains an unmet clinical need for effective and safe treatments for ADPKD. The extracellular Ca2+-sensing receptor (CaSR) is a regulator of epithelial ion transport. FDA-approved CaSR activator cinacalcet can reduce cAMP-induced Cl- and fluid secretion in various epithelial cells by activating phosphodiesterases (PDE) that hydrolyze cAMP. Since elevated cAMP is a key mechanism of ADPKD progression by promoting cell proliferation, cyst formation and enlargement (via Cl- and fluid secretion), here we tested efficacy of cinacalcet in cell and animal models of ADPKD. Cinacalcet treatment reduced cAMP-induced Cl- secretion and CFTR activity in MDCK cells as suggested by ∼70 % lower short-circuit current (Isc) changes in response to forskolin and CFTRinh-172, respectively. Cinacalcet treatment inhibited forskolin-induced cAMP elevation by 60 % in MDCK cells, and its effect was completely reversed by IBMX (PDE inhibitor). In MDCK cells treated with forskolin, cinacalcet treatment concentration-dependently reduced cell proliferation, cyst formation and cyst enlargement by up to 50 % without affecting cell viability. Cinacalcet treatment (20 mg/kg/day for 7 days, subcutaneous) reduced renal cyst index in a mouse model of ADPKD (Pkd1flox/flox;Ksp-Cre) by 20 %. Lastly, cinacalcet treatment reduced cyst enlargement and cell proliferation in human ADPKD cells by 60 %. Considering its efficacy as shown here, and favorable safety profile including extensive post-approval data, cinacalcet can be repurposed as a novel ADPKD treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pediatrics, University of California, San Francisco, 513 Parnassus Avenue, HSE 1244, San Francisco, CA, 94143, United States.
- Department of Pediatrics, University of California, San Francisco, 513 Parnassus Avenue, HSE 1244, San Francisco, CA, 94143, United States. Electronic address: onur.cil@ucsf.edu.
Förderung
- NIDDK NIH HHS
- National Institutes of Health
- University of Kansas
- University of Maryland
Zitieren
APA
Yottasan, P., Chu, T., Chhetri, P. D., & Cil, O. (2024). Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment. Translational Research. https://doi.org/10.1016/j.trsl.2023.10.005
Vancouver
Yottasan P, Chu T, Chhetri PD, Cil O. Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment. Translational Research. 2024. doi:10.1016/j.trsl.2023.10.005
BibTeX
@article{Yottasan2024,
author = {Yottasan, Pattareeya and Chu, Tifany and Chhetri, Parth D and Cil, Onur},
title = {Repurposing calcium-sensing receptor activator drug cinacalcet for ADPKD treatment},
journal = {Translational Research},
year = {2024},
doi = {10.1016/j.trsl.2023.10.005}
}
EUVIMED